SynthesisClinical and experimental medicine2025
Anti-inflammatory mechanism of resveratrol's Triglyceride-lowering effect in hyperlipidemia: a meta-analysis integrated network pharmacology and molecular dynamics simulation.
Synthesis in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Integrative Evidence on Mulberry Extract for Modulating Metabolic Risk Factors Associated with Vascular Dementia.International journal of molecular sciences · 2025Pooled it
- Resveratrol Supplementation and its Potential Benefits in Obesity-related Non-communicable Diseases.In vivo (Athens, Greece)Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To elucidate resveratrol's (RES) effects on blood lipids and underlying mechanisms, this study integrated meta-analysis with network pharmacology and molecular dynamics simulations. Randomized controlled trials (RCTs) were systematically retrieved, screened, and assessed for quality, followed by meta-analysis. Separately, shared targets of RES and hyperlipidemia were identified, and protein-protein interaction networks were constructed using Cytoscape. Core targets were validated via molecular docking and 100 ns molecular dynamics simulations. Meta-analysis of seven RCTs (n = 337) revealed that RES significantly reduced triglycerides (TG) but showed no significant effects on total cholesterol, low-density lipoprotein, or high-density lipoprotein. Network pharmacology identified 794 RES-hyperlipidemia overlapping targets, with PPI analysis prioritizing three pro-inflammatory hubs: Interleukin-6 (IL6), Interleukin-1β (IL1B), and tumor necrosis factor. Molecular dynamics simulations confirmed stable RES binding to these targets, with strong binding free energies of - 13.95, - 11.86, and - 11.28 kcal/mol, respectively. RES specifically lowered TG but not other lipids, potentially through direct modulation of inflammatory pathways rather than classic lipid metabolism regulators. Comprehensive analysis indicated RES as a promising therapeutic candidate for hypertriglyceridemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.